In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other mid-cap healthcare stocks. According to projections by ReportLinker ...

Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) on September 13. The company’s shares closed last Friday at $37.62.

Below is Validea's guru fundamental report for APELLIS PHARMACEUTICALS INC (APLS). Of the 22 guru strategies we follow, APLS rates highest using our P/B Growth Investor model based on the ...

Short interest in Apellis Pharmaceuticals Inc (NASDAQ:APLS) decreased during the last reporting period, falling from 16.27M to 16.17M. This put 18.34% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant ...